PMID- 2539290
OWN - NLM
STAT- MEDLINE
DCOM- 19890515
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 37
IP  - 2
DP  - 1989 Feb
TI  - Enalapril. An update of its pharmacological properties and therapeutic use in 
      congestive heart failure.
PG  - 141-61
AB  - Enalapril provides significant haemodynamic, symptomatic and clinical improvement 
      when added to maintenance therapy with digitalis and diuretics in patients with 
      congestive heart failure [NYHA (New York Heart Association) classes II to IV]. 
      These effects are not attenuated during long term therapy. More significantly, a 
      clinical study demonstrated that enalapril reduces mortality when added to 
      established therapy in patients with severe congestive heart failure (NYHA class 
      IV) refractory to digitalis, diuretics and other vasodilators. Thus, ACE 
      inhibitors such as enalapril offer a significant advance in the treatment of 
      congestive heart failure. Because these drugs improve symptoms in patients with 
      classes II to IV failure, and reduce mortality in patients with severe heart 
      failure, they should be considered as first choice adjuvant therapy when a 
      vasodilator is needed in addition to conventional treatment with digitalis and 
      diuretics.
FAU - Todd, P A
AU  - Todd PA
AD  - ADIS Drug Information Services, Auckland, New Zealand.
FAU - Goa, K L
AU  - Goa KL
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 69PN84IO1A (Enalapril)
SB  - IM
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - *Enalapril/administration & dosage/adverse effects/pharmacology/therapeutic use
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Random Allocation
RF  - 120
EDAT- 1989/02/01 00:00
MHDA- 1989/02/01 00:01
CRDT- 1989/02/01 00:00
PHST- 1989/02/01 00:00 [pubmed]
PHST- 1989/02/01 00:01 [medline]
PHST- 1989/02/01 00:00 [entrez]
AID - 10.2165/00003495-198937020-00004 [doi]
PST - ppublish
SO  - Drugs. 1989 Feb;37(2):141-61. doi: 10.2165/00003495-198937020-00004.